Silo Pharma (SILO) said Wednesday that it has signed a service agreement with medical technology firm Resyca for a drug-device study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder, or PTSD.
Financial details were not disclosed.
Silo said the study is expected to provide the necessary device data and documentation for SPC-15's investigational new drug application, which the company plans to submit to the US Food and Drug Administration this year.
Silo is currently conducting two additional SPC-15 studies, it said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。